GSK’s Darapladib Poised To Become Latest Cardiovascular Outcomes Casualty
This article was originally published in The Pink Sheet Daily
Executive Summary
Company announces that Lp-PLA2 inhibitor darapladib fails Phase III STABILIITY outcomes study, the latest in a string of pharma CV failures.
You may also be interested in...
Surprise! It’s A Phase III Failure
When Phase III clinical trial failures happen it is a painful blow – to the drug manufacturer, to investors and to patients. Scrip takes a look at some of the biggest Phase III surprises since 2010.
GSK Likes Its Go-It-Alone Strategy Over A Mega-Merger
GlaxoSmithKline’s solo strategy is the right one, CEO Andrew Witty said, brushing aside questions about a potential merger with Pfizer during the company’s third quarter sales and earnings call.
Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback
GlaxoSmithKline’s decision to end a Phase III trial testing the cancer immunotherapy MAGE-A3 in NSCLC is no surprise, following disappointing results in two trials, but coupled with other disappointing R&D news it puts more pressure on the company to deliver on its respiratory launches.